{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:22:18Z","timestamp":1792120938047,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["VU 2013-6411"],"award-info":[{"award-number":["VU 2013-6411"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejca.2024.114153","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T20:24:38Z","timestamp":1717705478000},"page":"114153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial"],"prefix":"10.1016","volume":"207","author":[{"given":"M.R.","family":"Seefat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.M.","family":"Stege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.I.","family":"Lissenberg-Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.J.","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hoogendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.F.","family":"Ypma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.","family":"Velders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Westerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Strobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Durdu-Rayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Davidis-van Schoonhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.W.","family":"van Kampen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Silbermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"van der Spek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Beeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Erjavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.C.H.P.","family":"de Graauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.L.","family":"Leys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nasserinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Blommestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.J.","family":"Cucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10272","key":"10.1016\/j.ejca.2024.114153_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2024.114153_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-Related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA Trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.114153_bib3","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ejca.2024.114153_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Aging ESo, Hematology. Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.114153_bib5","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1016\/S2666-7568(22)00172-6","article-title":"Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study","volume":"3","author":"Efficace","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"13","key":"10.1016\/j.ejca.2024.114153_bib6","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2024.114153_bib7","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","article-title":"Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany","volume":"21","author":"Engelhardt","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.ejca.2024.114153_bib8","first-page":"599","article-title":"Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey","volume":"21","author":"Acaster","year":"2013","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2024.114153_bib9","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/annonc\/mdy228","article-title":"Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide","volume":"29","author":"Scotte","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114153_bib10","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2018.36.15_suppl.10009","article-title":"Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT)","volume":"36","author":"Soto-Perez-De-Celis","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114153_bib11","volume":"132","author":"Stege","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2024.114153_bib12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2024.114153_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114153_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the research and treatment of cancer quality of life questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114153_bib15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ejh.13316","article-title":"Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients","volume":"103","author":"Sully","year":"2019","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114153_bib16","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3324\/haematol.2019.222299","article-title":"Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study","volume":"105","author":"Nielsen","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ejca.2024.114153_bib17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ejca.2024.114153_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ejh.13379","article-title":"Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial","volume":"104","author":"Schjesvold","year":"2020","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114153_bib19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00277-014-2264-0","article-title":"Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry","volume":"94","author":"van der Poel","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2024.114153_bib20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejca.2017.06.025","article-title":"A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials","volume":"83","author":"Hamel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.114153_bib21","first-page":"171","article-title":"A point of minimal important difference (MID): a critique of terminology and methods","volume":"11","author":"King","year":"2011","journal-title":"Expert Rev Pharm Outcomes Res"},{"issue":"1","key":"10.1016\/j.ejca.2024.114153_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/s12885-021-08325-2","article-title":"Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial","volume":"21","author":"Knop","year":"2021","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2024.114153_bib23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Cl Lymph Myelom Leuk"},{"issue":"4","key":"10.1016\/j.ejca.2024.114153_bib24","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ejca.2024.114153_bib25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jclinepi.2006.10.006","article-title":"Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis","volume":"60","author":"Viala","year":"2007","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114153_bib26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1600-0609.2008.01126.x","article-title":"Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma","volume":"81","author":"Strasser-Weippl","year":"2008","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114153_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2141.1997.222667.x","article-title":"Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group","volume":"97","author":"Wisloff","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2024.114153_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-187202","article-title":"Health-related quality of life (HRQoL) in fit, unfit and frail patients enrolled in fitness (UK-MRA Myeloma XIV): a cross sectional study","volume":"142","author":"McCourt","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.114153_bib29","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood-2022-165524","article-title":"Health-related quality of life for frail transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone: subgroup analysis of MAIA trial","volume":"140","author":"Perrot","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2024.114153_bib30","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00277-021-04592-y","article-title":"Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"100","author":"Nakazato","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114153_bib31","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.ejca.2024.114153_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102693","article-title":"New strategies for the treatment of older myeloma patients","volume":"15","author":"Larocca","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ejca.2024.114153_bib33","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s11136-023-03404-2","article-title":"Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study","volume":"32","author":"de Ligt","year":"2023","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2024.114153_bib34","first-page":"37","article-title":"Managing treatment-related peripheral neuropathy in patients with multiple myeloma","volume":"6","author":"Grammatico","year":"2016","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.ejca.2024.114153_bib35","doi-asserted-by":"crossref","DOI":"10.1017\/S204579602100038X","article-title":"Uncovering survivorship bias in longitudinal mental health surveys during the COVID-19 pandemic","volume":"30","author":"Czeisler","year":"2021","journal-title":"Epidemiol Psychiatr Sci"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:22:27Z","timestamp":1786969347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":35,"alternative-id":["S0959804924008098"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114153","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114153"}}